BACKGROUND: Immunofluorescence testing is an important tool for diagnosing @entity4530 . OBJECTIVE: To characterize the immunofluorescence findings in @entity1 diagnosed with autoimmune blistering @entity272 . METHODS: We retrospectively analyzed immunofluorescence results encompassing a 10-year period. RESULTS: 421 @entity1 were included and divided into 2 groups: group 1- intraepidermal @entity4530 (n=277) and 2- subepidermal @entity4530 (n=144). For group 1, positive DIF findings demonstrated: predominance of IgG intercellular staining (ICS) and C3 for pemphigus foliaceus-PF (94% and 73% respectively), @entity7271 (91.5%-79.5%) and @entity68341 (66%-33%); ICS IgA in 100% of IgA pemphigus cases, and IgG deposits in the basement membrane zone (BMZ) along with ICS in one @entity19359 @entity1 . The IIF findings revealed mean titers of 1:2.560 for PV and 1:1.280 for PF. For @entity7271 , IIF was positive in 2 out of 3 cases with @entity35 bladder substrate. In group 2, positive DIF findings included multiple deposits at basement membrane zone for epidermolysis bullosa acquisita-EBA (C3-89%,IgG-79%,IgA-47%,IgM-21%) mucous membrane pemphigoid-MMP (C3,IgG,IgA,IgM-80%) and bullous pemphigoid-BP (C3-91%,IgG-39%,IgA-11%,IgM-6%), and IgA at basement membrane zone for @entity7490 (99%) and @entity14086 (dermal papillae in 84.6%). For @entity9338 , there was C3 (100%) and IgG (50%) deposition at basement membrane zone. indirect immunofluorescence positive findings revealed basement membrane zone IgG deposits in 46% of BP @entity1 , 50% for EBA, 15% for @entity7490 and 50% for LPP. Indirect immunofluorescence positive results were higher for BP and EBA with Salt-Split skin substrate. CONCLUSION: Our results confirmed the importance of immunofluorescence assays in diagnosing @entity792 , and higher sensitivity for indirect immunofluorescence when Salt-split skin technique is performed.

Immunofluorescence testing in the diagnosis of XXXX : overview of 10-year experience.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity7271 :: ('MESH:D010392', 'Disease') :: ['paraneoplastic pemphigus', 'pemphigus vulgaris-PV'] @entity4530 :: ('MESH:D001768', 'Disease') :: ['blistering diseases'] @entity14086 :: ('MESH:D003874', 'Disease') :: ['dermatitis herpetiformis-DH'] @entity68341 :: ('MESH:C562587', 'Disease') :: ['paraneoplastic pemphigus-PNP'] @entity19359 :: ('MESH:D016506', 'Disease') :: ['Hailey-Hailey'] @entity9338 :: ('MESH:D008010', 'Disease') :: ['lichen planus pemphigoides'] @entity272 :: ('MESH:D012871', 'Disease') :: ['skin diseases'] @entity35 :: ('10116', 'Species') :: ['rat'] @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune blistering diseases'] @entity7490 :: ('MESH:D062027', 'Disease') :: ['IgA linear disease', 'IgA linear dermatosis']
@entity792 :: (MESH:D001327,Disease) :: ['autoimmune blistering diseases']
